Other Cancer Types

Additional polydatin oncology evidence across nasopharyngeal, cervical, ovarian, and other cancer models - work in progress

Polydatin has been studied in several additional cancer types beyond the better-developed colorectal, breast, lung, liver, oral, and blood-cancer literature.

Other areas with preliminary evidence

Nasopharyngeal cancer

Cytotoxic effects reported in cell-line studies

Laryngeal and cervical cancer

Cell-cycle arrest and apoptosis linked to PDGF/Akt suppression, cytochrome c release, and PARP-related signalling

Ovarian cancer

Antigrowth activity reported in 3D aggregate models
Oxidative-stress and redox biology remain relevant themes

Brain-tumour relevance through resveratrol conversion

Polydatin contributes to the systemic resveratrol pool after metabolism, which is relevant to ongoing interest in blood-brain barrier penetration and brain-tumour contexts. That does not make polydatin a proven brain-cancer treatment, but it keeps the topic clinically relevant for CNS-focused readers.

Practical interpretation

These are promising but still secondary evidence areas. They help expand the biological scope of polydatin, but should not be weighted the same as its stronger models.

References

Uncovering the Anticancer Potential of Polydatin: A Mechanistic Insight
https://pmc.ncbi.nlm.nih.gov/articles/PMC9656535/

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.